Drug Profile
Research programme: influenza monoclonal antibodies - Johnson & Johnson Innovative Medicine
Alternative Names: CR 8043; CR-8033; CR-8071; flu-mAb; flumab; H5N1 virus antibodies - Crucell; Pandemic influenza antibodies - CrucellLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator AIMM Therapeutics; Crucell
- Developer Crucell
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Influenza-virus-infections in Netherlands (Parenteral)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Netherlands (Parenteral)
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)